Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, nonacog gamma (Rixubis®) cannot be endorsed for use within NHS Wales for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). Rixubis is indicated in patients of all age groups. This product is currently not marketed in the UK. |
||
|
||
Medicine details |
||
| Medicine name | nonacog gamma (Rixubis®) | |
| Formulation | 250 IU powder and solvent for solution for injection, 500 IU powder and solvent for solution for injection, 1000 IU powder and solvent for solution for injection, 2000 IU powder and solvent for solution for injection, 3000 IU powder and solvent for solution for injection | |
| Reference number | 2271 | |
| Indication | For the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). |
|
| Company | Baxter Healthcare Ltd | |
| BNF chapter | Cardiovascular system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 15/05/2015 | |
| Date of issue | 20/05/2015 | |